All episodes
Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer
Episode 443: ESMO 2025 Bladder Cancer Preview
Episode 441: The History of IO in Urothelial Cancer - Part 2
Episode 440: The History of IO in Urothelial Cancer - Part 1
Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer
Episode 438: The History of Testis Cancer Treatment
Episode 437: Uromigos Japan - バルバーサ (Erdafitinib)を実臨床でどう使うか!
Episode 436: The History of IO in RCC - Part 2
Episode 435: The History of IO in RCC - Part 1
Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC
Episode 433: Uromigos Japan - 改訂版ASCO mCRPCガイドライン
Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap
Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials
Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?
Episode 429: ASCO2025レポート
Episode 428: ASCO 2025 Recap
Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)
Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC
Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI
Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session
Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC
Episode 422: ACSO 2025 - ctDNA data from NIAGARA
Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer
Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer
Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study
Episode 418: ASCO 2025 - Biomarkers in RCC
Episode 417: ASCO25 GUの注目演題について3人でDiscussion!!
Episode 416: ASCO 2025 Preview
Episode 415: Uromigos Score 前立腺がん編
Episode 414: Uromigos score en cáncer de próstata metastasico - más allá de las guías clínicas
Episode 413: The Uromigos Score for Advanced Prostate Cancer
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1
Episode 411: Live from EIKCS in Amsterdam - RCC Highlights
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC
Episode 408: Uromigos Japan - European Delphi Study of mRCCについてdiscussion
Episode 407: Drug Development in China: Part 2 of 2
Episode 406: Drug Development in China: Part 1 of 2
Episode 405: The Good News About Cancer podcast
Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands
Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands
Episode 402: Uromigos en Espanol: Futuro del carcinoma de células renales
Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands
Episode 400: The Uromigos Score for Urothelial Cancer
Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers?
Episode 398: Reflections on the Felix Feng Symposium at ASCO GU
Episode 397: APCCC Diagnostics Conference recap
Episode 396: Uromigos Japan - 激論 @JSMO25
Episode 395: Uromigos Japan: ASCO GU 2025のレビュー
Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025
Episode 393: ASCO GU 2025 Review Podcast
Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC
Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214
Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update
Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes
Episode 386: ASCO GU 2025 - APRI Meta-analysis
Episode 385: ASCO GU 2025 - TALAPRO-2
Episode 384: ASCO GU Preview
Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC
Episode 382: Uromigos Japan - TROPICs-04の考察
Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
Episode 380: The Role of SBRT in RCC
Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る
Episode 378: 2025 Preview of Important GU Data
Episode 377: Prostate Cancer 2024 Highlights
Episode 376: Bladder Cancer 2024 Highlights
Episode 375: Renal Cancer 2024 Highlights
Episode 374: Mechanisms of HIF Resistance
Episode 373: KEYNOTE-564 Asian OSとANNARの解説
Episode 372: FDA Accelerated Approval Process
Episode 371: TROPICS-04 Results from ESMO Asia
Episode 370: Artificial Intelligence in Medical Oncology
Episode 369: Paper of the Month with Bishoy Faltas
Episode 368: Radiomics in RCC: Live from IKCS
Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer
Episode 366: ARPIs in Prostate Cancer - Are They Different?
Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC)
Episode 364: 腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
Episode 363: 前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
Episode 362: 膀胱がんの最新の話題〜周術期薬物療法とADC〜
Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer
Episode 360: The SUNRISE Program in Bladder Cancer
Episode 359: #UromigosLive24 - IO after IO in RCC
Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer
Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC
Episode 355: #UromigosLive24 - Radioligands in prostate cancer
Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer
Episode 353: #UromigosLive24 ADC session
Episode 352: ESMO 2024 - RCC and Bladder review
Episode 351: ESMO 2024 review part 1: prostate cancer
Episode 350: ESMO 2024 - NIAGARA
Episode 349: ESMO 2024 - Uromigos Japan!!
Episode 348: ESMO 2024 - UpFrontPSMA
Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer
Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC
Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC
Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC